Skip to content
Optionomics

CDLX earnings analysis

10-Q · Filed November 5, 2026 · Our reading of the company's report

The latest report

Cardlytics reported a sharp third-quarter contraction, with revenue down 30% year over year to $32.882 million and monthly qualified users down 43.7 million to 186.633 million. GAAP net loss improved to $8.947 million…

Read full summary

Cardlytics reported a sharp third-quarter contraction, with revenue down 30% year over year to $32.882 million and monthly qualified users down 43.7 million to 186.633 million. GAAP net loss improved to $8.947 million because the prior-year period included a $58.843 million impairment, but adjusted EBITDA fell to $0.386 million and operating cash flow remained negative. Liquidity was supported by $23.0 million of net Bridg-sale proceeds, but cash declined to $29.947 million and management expects additional operating losses, making the outlook bearish despite lower expenses and improved GAAP loss.

Read the original on SEC.gov

Gross and operating margin

How much of each revenue dollar the business keeps.

50% Gross margin Operating margin Aug 2023 Nov 2026

One point per quarterly or annual filing. Both margins are shares of that report's revenue.

From revenue to operating profit

Where each $100 of revenue went in this report.

Of every $100 of revenue Cost of sales $51 Operating expenses $66 Left as operating profit $-17

Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.

How we read each report

Our analysis across the last few reports.

Read as bullish Read as bearish Aug 2023 Nov 2026

Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.

What stood out

  • Revenue and billings contracted sharply

    Third-quarter revenue was $32.882 million, down $14.080 million, or 30%, from $46.962 million in the prior-year quarter. Billings declined 32% to $57.224 million from $84.124 million, primarily because of changes in bank-partner relationships.

  • Operating loss improved materially

    Gross profit was $16.242 million versus $21.429 million, implying a gross margin of approximately 49.4% versus 45.6% in the prior-year quarter. Operating loss improved substantially to $5.421 million from $66.449 million, primarily because the prior-year period included a $58.843 million goodwill and intangible-asset impairment.

  • Net loss improved, EBITDA weakened

    Net loss narrowed to $8.947 million from $72.673 million, while adjusted EBITDA declined to $0.386 million from $3.339 million. The improvement in GAAP net loss was therefore driven largely by the absence of the prior-year impairment rather than stronger operating earnings.

  • User base and contribution declined

    Cardlytics monthly qualified users fell to 186.633 million from 230.329 million, a decrease of 43.7 million, primarily because a U.S. financial-institution partner exited the platform. Adjusted contribution declined to $19.397 million from $25.565 million and ACPU decreased to $0.10 from $0.11.

  • Cash generation remained negative

    Nine-month operating cash flow was negative $20.138 million versus negative $3.720 million in the prior-year period, while nine-month free cash flow was negative $20.277 million versus negative $16.945 million. Third-quarter free cash flow improved to negative $1.629 million from negative $2.703 million, partly reflecting a $6.442 million legal indemnification payment included in the FCF reconciliation.

  • Divestiture bolstered near-term liquidity

    The Bridg sale generated $23.0 million of net cash proceeds from the sale of PAR shares, and the company had $29.947 million of cash and $10.421 million of unused borrowings at September 30, 2026. Net borrowings under the revolving credit facility were $25.0 million, and the facility requires at least $20.0 million of unrestricted cash.

What to watch

  • Continued losses pressure liquidity

    Management states that it expects additional operating losses in the near term and may require additional capital resources. Cash and cash equivalents declined to $29.947 million from $48.719 million at December 31, 2025, while nine-month operating cash use was $20.138 million.

  • Bridg divestiture may reduce scale

    The company added a risk that it may not achieve the anticipated benefits of the Bridg Sale. Bridg represented approximately 9% of 2025 total revenue, and management says the company’s operational and financial profile and exposure to risks in the remaining business have changed following the sale.

  • Nasdaq compliance risk added

    The company added a Nasdaq delisting risk, including a $1.00 minimum closing-price requirement and a $15.0 million minimum market value of publicly held shares. Delisting could reduce liquidity and impair the company’s ability to raise additional capital, while also constituting a fundamental change under the notes indenture.

Management's outlook

The 10-Q provides no numeric revenue or EPS guidance. Management expects additional operating losses in the near term but believes liquidity is sufficient to fund operations and capital requirements for at least the next 12 months.

Earlier filings 4

10-Q · May 7, 2026

Cardlytics reported a Q1 2026 revenue of $34.3 million, down 39% year-over-year, falling short of estimates of $37.1 million. Despite missing on revenue, the company showed an EPS of -$0.11, an improvement from the…

10-K · March 4, 2026

Cardlytics positions itself as a commerce media platform built on a financial media network (Cardlytics) and a POS/identity platform (Bridg). The company highlights network effects and data scale — analyzing…

10-Q · November 5, 2025

Cardlytics reported Q3 2025 revenue of $52.0M and GAAP net loss of $72.7M (EPS $(1.36)). Revenue declined year-over-year but gross margin improved; operating loss narrowed materially versus prior-year quarter. The…

10-Q · August 6, 2025

Cardlytics reported Q2 2025 revenue of $63,249,000, a small sequential increase versus Q1 2025 ($61,898,000) but a year-over-year decline versus Q2 2024 ($69,636,000). Operating loss improved to $12,789,000 in Q2 2025…

Smart money in CDLX

Totals from the last full session. Insider and politician figures cover 90 days.

This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.

See every CDLX trade live.

The free pages stop at the last full session. Trader shows every trade as it prints.

Start tracking No card needed.